Goldman Sachs Upgrades Teva Pharma (TEVA) to Buy
Get Alerts TEVA Hot Sheet
Price: $13.18 +0.69%
Rating Summary:
12 Buy, 25 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 13 | New: 18
Rating Summary:
12 Buy, 25 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 13 | New: 18
Join SI Premium – FREE
Goldman Sachs upgraded Teva Pharma (NYSE: TEVA) from Neutral to Buy with a price target of $75.00.
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $61.70 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi Upgrades Hancock Whitney (HWC) to Buy
- Citi Upgrades Unibail-Rodamco-Westfield (URW:NA) (UNBLF) to Buy
- Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
Create E-mail Alert Related Categories
Hot Upgrades, UpgradesRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!